Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (28) clinical trials

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Phase

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Phase

The primary objectives of this study are to assess the effects of RVT-101 versus placebo as adjuncts to stable donepezil therapy on cognitive function as measured by the Alzheimer’s Disease Assessment Scale - Cognitive Subscale 11 items (ADAS-Cog-11) after 24 weeks of treatment AND on activities of daily living as ...

Phase

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

52 week duration Lab testing physical exams mental scales PET and MRI scans

Phase

Researchers are conducting a local research study for an investigational drug in people with mild Alzheimer's disease.

Phase

EXPEDITION 3 will look at whether the investigational drug solanezumab can help slow the worsening of AD in patients with mild disease. Study duration will be approximately 18 months, followed by an optional open-label extension study. Participants will be randomized in a 1:1 ratio to receive solanezumab or placebo by ...

Phase